Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)

17 de novembro de 2026 atualizado por: Goksu Goc, American Hospital 2 Kosovo

Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Visão geral do estudo

Descrição detalhada

Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.

Tipo de estudo

Observacional

Inscrição (Estimado)

160

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Pristina, Kosovo, 10000
        • American Hospital Kosova
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 42 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Método de amostragem

Amostra Não Probabilística

População do estudo

Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.

Descrição

Inclusion Criteria:

  1. Woman aged 18 to 42 years.
  2. Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
  3. Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
  4. First eligible (index) cycle during the study period; both ovaries present.
  5. Written informed consent for data collection and processing.

Exclusion Criteria:

  1. Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
  2. Non-antagonist protocol (for example, long GnRH-agonist).
  3. Oocyte-donation or fertility-preservation (egg-freezing) cycle.
  4. A prior cycle of the same woman already enrolled in the study.
  5. Inability to provide informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Lower starting dose (150 international units [IU] or less)

Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Higher starting dose (more than 150 IU)

Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of mature metaphase II (MII) oocytes retrieved
Prazo: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Total follicle-stimulating hormone (FSH) activity administered
Prazo: From the first to the last day of ovarian stimulation (up to 21 days)

Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity.

From the first to the last day of ovarian stimulation (up to 21 days)
Gonadotropin medication cost
Prazo: From the first to the last day of ovarian stimulation (up to 21 days)

Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Total number of oocytes retrieved
Prazo: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Oocyte maturity rate
Prazo: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Cycle cancellation before oocyte retrieval
Prazo: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)

Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure.

From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
Duration of ovarian stimulation
Prazo: From the first to the last day of ovarian stimulation (up to 21 days)

Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Number of normally fertilised oocytes with two pronuclei (2PN)
Prazo: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)

Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure.

At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
Number of usable embryos
Prazo: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
Number of blastocysts
Prazo: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Live birth (exploratory)
Prazo: Up to 12 months after the start of ovarian stimulation

Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively.

Up to 12 months after the start of ovarian stimulation
Clinical pregnancy (exploratory)
Prazo: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively.

At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

1 de outubro de 2028

Conclusão do estudo (Estimado)

1 de agosto de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever